A Promising Big Step Forward for Medical Marijuana
PALM BEACH, Florida, June 12, 2018 /PRNewswire/ --
MarketNewsUpdates.com Market Commentary
Medical marijuana has picked up considerable momentum after a U.S. Food and Drug Administration advisory panel unanimously recommended approval of GW Pharmaceuticals' epilepsy medication, Epidolex. The panel recommended approval of the drug to treat two forms of epilepsy -- Lennox-Gastaut syndrome and Dravet syndrome, which are the most difficult types of epilepsy to treat despite other currently available traditional medications. If the agency follows the recommendation, this would be the first cannabis-derived prescription medicine available in the U.S. and could be sold in the U.S. this year. Several other legitimate players in this medical marijuana sector include Scythian Biosciences Corporation (TSX-V:SCYB) (OTC:SCCYF), OrganiGram Holdings Inc. (TSX-V:OGI) (OTC:OGRMF), Corbus Pharmaceuticals (NASDAQ:CRBP), AbbVie Inc. (NYSE:ABBV) and Aphria Inc. (OTC:APHQF) (TSX:APH).
According to Aras Azadian, CEO of Avicanna, as quoted by Fluent Markets, "The Epidiolex results show further progress in the medical and evidence-based use of cannabinoids. This will help educate the medical community and help in convincing other clinicians to focus on cannabinoids as a possible treatment for other indications that it may be helpful for."
Whether it be GW Pharmaceuticals' childhood epilepsy medication, or Scythian Biosciences Corporation's (TSX-V: SCYB) (OTC: SCCYF) cannabis-based treatment for traumatic brain injury, there is a clear need for medical marijuana among patients.
Medical Marijuana Changing the Way We Treat Patients
"Thirty states already permit some form of medical cannabis use, and several more are poised to approve it this fall - a sign this now-beloved industry has dramatically altered public opinion among both conservatives and liberals," notes USA Today. "Among the most recent high-profile additions to the medical marijuana industry: former House speaker John Boehner, who is joining the Acreage board after decades of cannabis opposition."
One of the many companies leading the charge with marijuana treatment has been GW Pharmaceuticals where a "Food and Drug Administration advisory panel unanimously recommended approval of an epilepsy medication. If the agency follows the recommendation, as is expected, the drug would be the first cannabis-derived prescription medicine available in the United States," as reported by The New York Times.
The panel recommended approval of the drug to treat two rare forms of epilepsy -- Lennox-Gastaut syndrome and Dravet syndrome, which are the most difficult types of epilepsy to treat despite other currently available traditional medications.
Also, Zynerba Pharmaceuticals, a specialty pharmaceutical company that focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics is hard at work developing ZYN002, which is in clinical trials for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis.
Even Scythian Biosciences Corporation (TSX.V:SCYB) (OTCQB:SCCYF) also is just beginning to gain momentum, advancing its treatment efforts for concussions and traumatic brain injury with its proprietary cannabinoid-based combination drug therapy.
The Cannabis Commitment to Brain Trauma Remedies
Scythian Biosciences is currently advancing prevention and treatment efforts for concussion and traumatic brain injury with its proprietary cannabinoid-based combination drug therapy. It's doing so by using a compound known as cannabidiol (CBD), which is found naturally in the marijuana plant that can help reduce inflammation in the brain and the resulting pressure of injured brain tissue against the skull.
However, Scythian's ambitions doesn't stop there. The company has recently announced its letter of intent to acquire MMJ International Investments Inc., sole holder of an Argentina-based pharmaceutical import and distribution company. This move, along with Isodol's ability to export the pure, natural CBD anywhere in the world, including Argentina, Colombia, and Jamaica, could exponentially expedite Scythian's international footprint and industry advancements.
Most recently, the company announced a licensing agreement with Isodiol International Inc. - a market leader in pharmaceutical grade phytochemical compounds and an industry leader in the manufacturing and development of CBD consumer products, to import and distribute Isodiol products to certain countries in the Caribbean, Central America, and South America, including Argentina, Colombia and Jamaica.
"Scythian shares Isodiol's commitment to developing the purest and most advanced medical cannabis products for patients in need," said Rob Reid, CEO of Scythian Biosciences Corporation (TSX-V: SCYB) (OTC: SCCYF) "On the heels of Isodiol's milestone approval by the United Kingdom's Medicines and Healthcare Products Regulatory Agency, we're proud to be able to tap into Isodiol's experienced, top tier team of chemists, technicians and professors that yield the purest government-approved CBD oil available for the advancement of the industry's understanding and application of medical cannabis."
Potential Comparables:
AbbVie Inc. (NYSE:ABBV) - AbbVie has exposure to synthetic cannabinoids-derived medication through its drug, Marinol. AbbVie's Marinol has already been approved by the Food and Drug Administration. This drug treats nausea and vomiting caused by chemotherapy and restores hunger in AIDS patients.
OrganiGram Holdings Inc. (TSX-V:OGI) (OTCQB:OGRMF) - Organigram Inc. is a licensed producer of medical marijuana in Canada. The company is focused on producing the highest-quality, condition-specific medical marijuana for patients in Canada. Its portfolio includes dry cannabis and cannabis oil, along with accessories like vaporizers.
Corbus Pharmaceuticals (NASDAQ:CRBP) - CRBP focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases. The company's lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug that is in Phase III clinical trials for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases.
Aphria Inc. (OTCQB:APHQF) (TSX:APH) - Aphria is one of Canada's lowest-cost medical cannabis producers. The company sells its products through both retail and wholesale channels. It's also engaged in the research and development and commercial production of cannabis oil.
For more information onScythian Biosciences Corporation (TSX-V:SCYB) (OTCQB:SCCYF), please visitMarijuanastox.com for afree research report.
Marijuanastox.com (MS) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author (MS), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MS) has not independently verified or otherwise investigated all such information. None of the Author, MS, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated forty five hundred dollars by MS, a non-affiliated third party to distribute this release on behalf of Scythian Biosciences Corporation
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
Media Contact:
FN Media Group, LLC
info@marketnewsupdates.com
+1(561)325-8757
SOURCE MarketNewsUpdates.com
